References

Type 2 Diabetes Defeated

Holistic Treatments to Reverse Diabetes

Get Instant Access

1. U.S. Centers for Disease Control and Prevention. Diabetes: Disabling, Deadly, and on the Rise. http://www.cdc.gov/nccdphp: Accessed April 20, 2005.

2. U.S. Centers for Disease Control and Prevention. National Diabetes fact sheet. http://www. cdc.gov/diabets/pubs/: Accessed April 20, 2005.

3. CDC Diabetes program: http://www.cdc.gov/diabetes/statistics/prev/nationa/figpersons.htm: Accessed April 20, 2005.

4. American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003; 26: 917-932.

5. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type I and type 2 diabetes mellitus. JAMA 2003; 289: 2254-2264.

6. Diabetes Control and Complications Research Group: The effects of intensive treatment on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Eng J Med 329: 977-986, 1993.

7. UKPDS study group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetics. Lancet. 1998; 352: 837-853.

8. American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care 27: S15-35, 200.

9. Stewart KM, Wilson MF, Rider JM. Insulin Delivery Devices. Journal of Pharmacy Practice 2004. 17; 1:20-28.

10. Plevin S, Sadur C. Use of a prefilled insulin syringe (Novolin Prefilled) by patients with diabetes. Clin Ther 1993; 15 (2): 423-31.

11. Bohannon, N.J. Insulin delivery using pen devices. Postgrad Med 1999; 106 (5): 57-68.

12. Weller, C, Linder, M. Jet Injection of Insulin vs the syringe-and-needle method. JAMA, 1966, 195(10): 844-7.

13. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm

14. Harsh I, Rudolph JW: An assessment of continuous subcutaneous insulin infusion therapy in an academic clinic (abstract). Diabetes 49 (Suppl. 1): 100A, 1998.

15. Pickup J, Mattock M, and Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injection with type I diabetes: Meta-analysis on randomized controlled trials. BMJ 2002; 324: 1-6.

16. Cersosimo E, Jornsay D, Arce C, Rieff M, Feldman E, Defronzo R. Improved Clinical Outcomes With Intensive Insulin Pump Therapy In Type 1 Diabetes. Diabetes 2002; 51(Suppl 2):515.

17. Hissa MN, Hissa ASR, Bruin VMS, Fredrickson LP. Comparison between Continuous Subcutaneous Insulin Infusion and Multiple Insulin Injection Therapy in Type 1 Diabetes Mellitus: 18-Month Follow-Up. Endocr Pract 2002; 8: 411-416.

18. Mathur R, Sosa M, Somma L, Peters AL. Comparison of Glycemic Outcomes in Patients with Type 1 Diabetes (T1DM) on Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections (MDI) Therapy. Diabetes 2002; 51(Suppl.2): 434.

19. http://www.fda.gov/cder/foi/label/2000/21081lbl.pdf

20. Ratner RE, Hirsh IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes: US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000; 23: 639-643.

21. Doyle (Boland) EA, Weinzimer SA, Steffen AT and et al: A randomized, Prospective Trail Comparing the Efficacy of Continuous Insulin with Multiple Daily Injections Using Insulin Glargine. Diabetes Care: 2004; 27: 155-8.

22. Locke DR, Rigg LA: Hypoglycemia coma associated with subcutaneous insulin infusion by portable pump. Diabetes Care 1981; 4: 389-391.

23. Bode BW, Steed RD, Davidson PC: Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes care 1996; 19: 324-327.

24. Boland EA, Grey M, Oesterle A, and et al: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control and enhance coping in adolescents with type 1 diabetes: Diabetes Care 1999; 22: 1784-1799.

25. Eichner HL, Selam JL, Holleman CB, Worcester BR, Turner DS, Charles MA. Reduction Of Severe Hypoglycemic Events In Type I (Insulin Dependent) Diabetic Patients Using Continuous Subcutaneous Insulin Infusion. Diabetes Res 1988; 2: 189-193.

26. Hirsch IB, Farkas-Hirsch, Cryer PE. Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetic Patients with Hypoglycemic Unawareness. Diabetes, Nutrition & Metabolism 1991; 4: 41-43.

27. Perriello G, Defeo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. The Dawn Phenomenon in Type I (Insulin-Dependent) Diabetes Mellitus. Magnitude, Frequency, Variability, and Dependency on Glucose Counter regulation and Insulin Sensitivity. Diabetologia 1991; 34: 21-28.

28. Yogev Y, Chen R, Ben-Haroush A, Phillip M, Jovanovic L, M Hod. Continuous Glucose Monitoring for the Evaluation of Gravid Women with Type 1 Diabetes Mellitus. Obstetrics & Gynecology 2003; 4: 633-638.

29. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM: Accessed April 10, 2005.

30. http://www.fda.gov/cdrh/recalls/: Accessed April 10, 2005.

31. Bode BW, Gross TM, Thorton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999, 46:183-190.

32. Chase PH, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001, 107: 222-226.

33. Kaufman FR. Role of continuous glucose monitoring in pediatric patients. Diabetes Technol Ther 2000, 2 (Suppl. 1): S49-S52.

34. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose. Diabetes Care 2001, 24:1858-1862.

35. Monsod TP, Flanagan DE, Rife F, Saenz R, Caprio S, Sherwin RS, Tamborlane WV. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002, 25: 889-893.

36. Mastrototaro JJ. The MiniMed continuous Glucose monitoring system. Diabetes Technology & Therapeutics 2000, 2 (Suppl. 1): S13-S18.

37. Summary of Safety and Effectiveness Data for the MiniMed Continuous Glucose Monitoring System (CGMS). Food and Drug Administration, 1999 (publ. no. PMA P980022). http:// www.fda.gov/cdrh/mda/docs/p990026S008.pdf (accessed 4/20/05)

38. http://www.fda.gov/cdrh/mda/docs/p990026S008.pdf (accessed 4/20/05)

39. ECRI. GlucoWatch Biographer: An automatic, noninvasive glucose monitor. Health Devices 31(8): 295-302, 2002.

40. Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002, 25(6): 1185-1191.

41. Steil GM, Rebrin K, Mastrototaro J, Bernaba B, Saad MF. Determination of plasma glucose excursions with a subcutaneous glucose sensor. Diabetes Technology & Therapeutics 2003, 5(1): 27-31.

42. Gross TM, Ter Veer A. Continuous glucose monitoring in previously unstudied population subgroups. Diabetes Technology & Therapeutics 2000, 2(Suppl. 1): S27-S34.

43. Gross TM, Mastrototaro JJ. Efficacy and reliability of the continuous Glucose monitoring system. Diab Technology & Therapeutics 2000, 2(Suppl. 1): S19-S26.

44. Gross TM, Bode BW, Einhorn D, Kayne DM, Reed C, White NH, Mastrototaro JJ. Performance evaluation of the MiniMed Continuous Glucose Monitoring System during patient home use. Diabetes Technology & Therapeutics 2000, 2:49-56.

45. Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S, Cygnus Research Team. Clinical evaluation of the GlucoWatch biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosensors and Bioelectronics 16: 621-629, 2001.

46. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO, the Cygnus Research Team. Noninvasive Glucose Monitoring: Comprehensive Clinical Results. JAMA 282:1839-1844, 1999.

47. Garg SK, Potts RO, Ackerman NR, Fermi SJ, Tamada JA, Chase PH. Correlation of fingerstick blood glucose measurements with GlucoWatch Biographer glucose results in young subjects with type I diabetes. Diabetes Care 22: 1708-1714, 1999.

48. Guerci B, Floriot M, Bohme P, Durain D, Benichou M, Jellimann S, Drouin P. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 2003, 26 (3): 582-589.

49. Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycemic control in type 1 diabetic subjects. Diabetic Medicine 2003, 20: 1012-1015.

50. Djakoure-Platonoff C, Radermecker R, Reach G, Slama G, Selam JL. Accuracy of the continuous glucose monitoring system in inpatient and outpatient conditions. Diabetes & Metabolism 2003, 29: 159-162.

51. Salardi S, Zucchini S, Santoni R, Ragni L, Gualandi S, Cicognani A, Cacciari E. The glucose area under the profiles obtained with Continuous Glucose Monitoring System relationships with HBA1c in pediatric type 1 diabetic patients. Diabetes Care 2002, 25: 1840-1844.

52. Sharp P, Rainbow S. Continuous glucose monitoring and haemoglobin A1c. Ann Clin Biochem 2002, 39: 516-517.

53. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the Continuous Glucose Monitoring System - Clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001, 24: 2030-2034.

54. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003, 26: 1153-1157.

55. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: A controlled crossover study. Pediatrics 2003, 111: 933-938.

56. Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, Desai S, Harper W, Lopatin M, Bartkowiak M, Tamada J, Eastman R. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics 111: 790-794, 2003.

57. Cheyne E, Kerr D. Making 'sense' of diabetes: using a continuous glucose sensor in clinical practice. Diabetes/Metabolism Research and Reviews 2002, 18(Suppl. 1): S43-S48.

58. Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Belicar P, Guerci B, Selam JL, Brun JM, Riveline JP, Estour B, Catargi B; EVADIAC Study Group: Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraper-itoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 2003 Dec; 29(6):602-7.

59. Nathan DM, Dunn FL, Burch J, McKitrick C, Larkin M, Haggan C, Lavin-Tompkins J, Norman D, Rogers D, Simon D: Post prandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin dependent diabetes mellitus patients. AM J Med 100: 412-417, 1996.

60. Dunn FL, Nathan DM, Scavini M, Selam JL, Wingrove TG.: Long-term therapy of IDDM with an implantable insulin pump. The Implantable Insulin Pump Trial Study Group. Diabetes Care. 1997 Jan; 20(1): 59-63.

61. Charles MA. Programmable implantable insulin infusion devices and diabetes care. Diabetes Technol Ther. 1999; 1(1): 89-96.

62. Dunn FL, Nathan DM, Scavini M, Selam JL, Wingrove TG.: Long-term therapy of IDDM with an implantable insulin pump. The Implantable Insulin Pump Trial Study Group. Diabetes Care. 1997 Jan; 20(1): 59-63.

63. Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Belicar P, Guerci B, Selam JL, Brun JM, Riveline JP, Estour B, Catargi B; EVADIAC Study Group.: Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraper-itoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 2003 Dec; 29(6): 602-7.

64. Broussolle C, Jeandidier N, Hanaire-Broutin H, et al: French multicenter experience of implantable pump. Lancet 1994; 343: 514-515.

65. Renard E, Rostane T, carrier C, Marchandin H, et al: Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. Diabetes Metab. 2001 Feb; 27(1): 62-5.

66. Olsen CL, Chan E, Turner DS, et al: Insulin antibodies response after a long-term intraperitoneal insulin administration via implantable programmable insulin delivery system. Diabetes care 1994; 17:169-176.

67. Jeandidier N, Boivin S, Sapin R, Rosart-Ortega F, Uring-Lambert B, Reville P, Pinget M.: Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia. 1995 May; 38(5): 577-84.

68. Saydah S, Fradkin J, Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291: 335-342.

69. E. Renald. Implantable closed-loop glucose sensing and insulin delivery: the future for insulin pump therapy. Curr. Opin. Pharmacol. 2 (2002) 708-716.

70. E. Renard, R. Shah. M. Miller, et al. Accuracy of real-time blood glucose measurement by long-term sensor allows automated insulin delivery in diabetic patients. Diabetes 51 (suppl. 2) (2002) 508-p (A126).

71. Van Den Berghe G, Wouters P. Weeker F, et al. Intensive insulin in critically ill patients. NEJM. 2000; 345: (19): 1359-1367.

72. American College of Endocrinology. Consensus Development Conference on Inpatient Diabetes and Metabolic Control. http://www.aace.com/pub/ICC/inpatientStatement.php (accessed 5/10/05).

Was this article helpful?

0 0
Delicious Diabetic Recipes

Delicious Diabetic Recipes

This brilliant guide will teach you how to cook all those delicious recipes for people who have diabetes.

Get My Free Ebook


Post a comment